Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced its participation in the BofA Securities CNS Therapeutics Virtual Conference 2024. The event is scheduled for Monday, October 7, 2024, with Catalyst's presentation set for 9:50 am ET.
Richard J. Daly, President and CEO of Catalyst, along with other management team members, will represent the company. Catalyst is a commercial-stage biopharmaceutical firm focusing on in-licensing, developing, and commercializing novel medicines for rare and difficult-to-treat diseases.
A webcast of the presentation will be available on Catalyst's website under the Investors section, with a replay accessible for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha annunciato la sua partecipazione al BofA Securities CNS Therapeutics Virtual Conference 2024. L'evento è previsto per lunedì 7 ottobre 2024, con la presentazione di Catalyst fissata per 9:50 am ET.
Richard J. Daly, Presidente e CEO di Catalyst, insieme ad altri membri del team dirigenziale, rappresenterà l'azienda. Catalyst è una società biofarmaceutica in fase commerciale che si concentra sull'in-licensing, lo sviluppo e la commercializzazione di nuovi farmaci per malattie rare e difficili da trattare.
Un webcast della presentazione sarà disponibile sul sito di Catalyst nella sezione Investitori, con una registrazione accessibile per almeno 30 giorni dopo l'evento.
Catalyst Pharmaceuticals (Nasdaq: CPRX) anunció su participación en la BofA Securities CNS Therapeutics Virtual Conference 2024. El evento está programado para el lunes 7 de octubre de 2024, con la presentación de Catalyst programada para 9:50 am ET.
Richard J. Daly, Presidente y CEO de Catalyst, junto con otros miembros del equipo directivo, representará a la empresa. Catalyst es una firma biofarmacéutica en etapa comercial que se enfoca en el licenciamiento, desarrollo y comercialización de nuevos medicamentos para enfermedades raras y difíciles de tratar.
Una transmisión en vivo de la presentación estará disponible en el sitio web de Catalyst en la sección de Inversores, con una repetición accesible durante al menos 30 días después del evento.
카탈리스트 제약 (Nasdaq: CPRX)는 BofA 증권 CNS 치료제 가상 회의 2024에 참여한다고 발표했습니다. 이 행사는 2024년 10월 7일 월요일에 예정되어 있으며, 카탈리스트의 발표는 동부 표준시 오전 9시 50분으로 예정되어 있습니다.
리차드 J. 달리 카탈리스트의 회장 겸 CEO는 다른 경영진과 함께 회사를 대표할 것입니다. 카탈리스트는 희귀하고 치료하기 어려운 질병을 위한 새로운 약물을 인허가하고 개발 및 상용화하는 데 주력하는 상업 단계의 생명공학 회사입니다.
발표의 웹캐스트는 카탈리스트 웹사이트의 투자자 섹션에서 이용할 수 있으며, 행사 후 최소 30일 동안 다시 시청할 수 있습니다.
Catalyst Pharmaceuticals (Nasdaq: CPRX) a annoncé sa participation à la BofA Securities CNS Therapeutics Virtual Conference 2024. L'événement est prévu pour lundi 7 octobre 2024, avec la présentation de Catalyst prévue pour 9h50 ET.
Richard J. Daly, Président et CEO de Catalyst, représentera l'entreprise avec d'autres membres de l'équipe de direction. Catalyst est une entreprise biopharmaceutique en phase commerciale qui se concentre sur le licencement, le développement et la commercialisation de nouveaux médicaments pour des maladies rares et difficiles à traiter.
Une webdiffusion de la présentation sera disponible sur le site Web de Catalyst dans la section Investisseurs, avec un replay accessible pendant au moins 30 jours après l'événement.
Catalyst Pharmaceuticals (Nasdaq: CPRX) hat seine Teilnahme an der BofA Securities CNS Therapeutics Virtual Conference 2024 bekannt gegeben. Die Veranstaltung ist für Montag, den 7. Oktober 2024 angesetzt, wobei die Präsentation von Catalyst um 9:50 Uhr ET stattfinden wird.
Richard J. Daly, Präsident und CEO von Catalyst, wird gemeinsam mit anderen Mitgliedern des Managementteams das Unternehmen vertreten. Catalyst ist ein in der Kommerzialisierungsphase befindliches biopharmazeutisches Unternehmen, das sich auf das Lizenzieren, Entwickeln und Vermarkten neuer Arzneimittel für seltene und schwer zu behandelnde Krankheiten konzentriert.
Ein Webcast der Präsentation wird auf der Website von Catalyst im Bereich Investoren verfügbar sein, mit einem Replay, das mindestens 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming BofA Securities CNS Therapeutics Virtual Conference 2024 on Monday, October 7, 2024.
Presentation Details:
| Presentation: | Monday, October 7, 2024 | |
| Time: | 9:50 am ET | |
| Webcast Link | ||
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When is Catalyst Pharmaceuticals (CPRX) presenting at the BofA Securities CNS Therapeutics Virtual Conference 2024?
Who will be representing Catalyst Pharmaceuticals (CPRX) at the BofA Securities conference?
Where can investors access the webcast of Catalyst Pharmaceuticals' (CPRX) presentation?
How long will the replay of Catalyst Pharmaceuticals' (CPRX) presentation be available?
What is the focus of Catalyst Pharmaceuticals (CPRX) as a company?
